Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Hiroyasu, Shoda"'
Autor:
Satoshi Ikeda, Masahiro Tsuboi, Kazuko Sakai, Toshihiro Misumi, Hiroaki Akamatsu, Hiroyasu Shoda, Noriaki Sakakura, Atsushi Nakamura, Yasuhisa Ohde, Hidetoshi Hayashi, Kyoichi Okishio, Morihito Okada, Ichiro Yoshino, Jiro Okami, Kazuhisa Takahashi, Norihiko Ikeda, Masayuki Tanahashi, Yuichi Tambo, Haruhiro Saito, Shinichi Toyooka, Hidetoshi Inokawa, Toyofumi Chen‐Yoshikawa, Toshihide Yokoyama, Tatsuro Okamoto, Noriko Yanagitani, Masahide Oki, Makoto Takahama, Kenji Sawa, Hirohito Tada, Kazuhiko Nakagawa, Tetsuya Mitsudomi, Kazuto Nishio
Publikováno v:
Molecular Oncology, Vol 18, Iss 2, Pp 305-316 (2024)
The phase III IMPACT study (UMIN000044738) compared adjuvant gefitinib with cisplatin plus vinorelbine (cis/vin) in completely resected epidermal growth factor receptor (EGFR)‐mutated non‐small cell lung cancer (NSCLC). Although the primary endpo
Externí odkaz:
https://doaj.org/article/5ef9670861fa45fda1c2e13f031a8170
Autor:
Hiroaki Kanemura, MD, MPH, PhD, Toshihide Yokoyama, MD, Ryu Nakajima, MD, PhD, Atsushi Nakamura, MD, PhD, Hiroaki Kuroda, MD, PhD, Yoshitaka Kitamura, MD, PhD, Hiroyasu Shoda, MD, PhD, Nobuaki Mamesaya, MD, PhD, Yoshihiro Miyata, MD, PhD, Tatsuro Okamoto, MD, PhD, Kyoichi Okishio, MD, PhD, Masahide Oki, MD, PhD, Yuichi Sakairi, MD, PhD, Toyofumi Fengshi Chen-Yoshikawa, MD, PhD, Tadashi Aoki, MD, Tatsuo Ohira, MD, PhD, Isao Matsumoto, MD, PhD, Kiyonobu Ueno, MD, PhD, Takuro Miyazaki, MD, PhD, Haruhisa Matsuguma, MD, PhD, Hideoki Yokouchi, MD, PhD, Tomoyuki Otani, MD, Akihiko Ito, MD, PhD, Kazuko Sakai, PhD, Yasutaka Chiba, PhD, Kazuto Nishio, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Isamu Okamoto, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Masayuki Takeda, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 4, Pp 100658- (2024)
Introduction: Immune checkpoint inhibitors have recently been approved for the treatment of early-stage NSCLC in the perioperative setting on the basis of phase 3 trials. However, the characteristics of such patients who are susceptible to recurrence
Externí odkaz:
https://doaj.org/article/6165423210284cf69a0cf2aac07b491b
Autor:
Junko Tanizaki, MD, PhD, Hiroaki Kuroda, MD, PhD, Toshihide Yokoyama, MD, Makoto Takahama, MD, PhD, Hiroyasu Shoda, MD, PhD, Atsushi Nakamura, MD, PhD, Yoshitaka Kitamura, MD, PhD, Nobuaki Mamesaya, MD, PhD, Yoshihisa Kadota, MD, PhD, Kenji Sawa, MD, PhD, Kyoichi Okishio, MD, PhD, Morihito Okada, MD, PhD, Chihiro Suminaka, MS, Kenta Noda, PhD, Kazuko Sakai, PhD, Yasutaka Chiba, PhD, Kazuto Nishio, MD, PhD, Kenji Chamoto, PhD, Tasuku Honjo, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Hidetoshi Hayashi, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 12, Pp 100590- (2023)
Introduction: Perioperative treatment in NSCLC has gained marked attention with the introduction of immune checkpoint inhibitors. Such a paradigm shift has given us additional opportunities to evaluate potential biomarkers in patients with these cura
Externí odkaz:
https://doaj.org/article/3f386ee3f72d427a96a00d99cb19bacc
Autor:
Naokazu Watari, Kakuhiro Yamaguchi, Hiroaki Terada, Kosuke Hamai, Ken Masuda, Yoshifumi Nishimura, Shinjiro Sakamoto, Takeshi Masuda, Yasushi Horimasu, Shintaro Miyamoto, Taku Nakashima, Hiroshi Iwamoto, Hiroyasu Shoda, Nobuhisa Ishikawa, Kazunori Fujitaka, Kozue Miyazaki, Yoshihiro Miyata, Hironobu Hamada, Kazuo Awai, Noboru Hattori
Publikováno v:
BMC Pulmonary Medicine, Vol 22, Iss 1, Pp 1-9 (2022)
Abstract Background Mesenchymal-epithelial transition exon14 (METex14) skipping is one of the therapeutic driver oncogene mutations in non-small cell lung cancer (NSCLC), and can be treated with tepotinib and capmatinib. There is only one report on c
Externí odkaz:
https://doaj.org/article/bece7498093044a7bbb19690580de0ce
Autor:
Kosuke Hamai, Hiroki Tanahashi, Sayaka Ueno, Hanae Konishi, Mirai Matsumura, Akio Nomura, Kanako Nakamoto, Shoko Isoyama, Takuya Tanimoto, Hiroyasu Shoda, Nobuhisa Ishikawa
Publikováno v:
Thoracic Cancer, Vol 11, Iss 6, Pp 1716-1719 (2020)
A 90‐year‐old female was admitted to our hospital with a history of a dry cough. Chest computed tomography (CT) scan showed a tumor shadow, and CT‐guided lung biopsy revealed squamous cell carcinoma harboring an EGFR mutation. In addition, prog
Externí odkaz:
https://doaj.org/article/689310ba3a2a4976860bb1fa84fbe589
Publikováno v:
Haigan. 63:84-90
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::43b3fc4ef3b61ef8b5b1ba4e2e3f0198
https://doi.org/10.2482/haigan.63.84
https://doi.org/10.2482/haigan.63.84
Publikováno v:
Haigan. 63:27-32
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5588172f9eeab769ea6d1f56aa3835ad
https://doi.org/10.2482/haigan.63.27
https://doi.org/10.2482/haigan.63.27
Publikováno v:
Anticancer Research. 42:4805-4812
Many patients with advanced lung cancer develop brain metastasis (BM); however, few reports confirming the efficacy of immune checkpoint inhibitors (ICIs) plus chemotherapy in non-small cell lung cancer (NSCLC) patients with symptomatic BM have been
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c7fb1abb8e882ab8f7b2a557722a748
https://doi.org/10.21873/anticanres.15985
https://doi.org/10.21873/anticanres.15985
Publikováno v:
Haigan. 62:292-298
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f38f95592c5982c1426430f44a4b5807
https://doi.org/10.2482/haigan.62.292
https://doi.org/10.2482/haigan.62.292
Autor:
Wakako Daido, Takeshi Masuda, Nobuki Imano, Naoko Matsumoto, Kosuke Hamai, Yasuo Iwamoto, Yusuke Takayama, Sayaka Ueno, Masahiko Sumii, Hiroyasu Shoda, Nobuhisa Ishikawa, Masahiro Yamasaki, Yoshifumi Nishimura, Shigeo Kawase, Naoki Shiota, Yoshikazu Awaya, Tomoko Suzuki, Soichi Kitaguchi, Kazunori Fujitaka, Yasushi Nagata, Noboru Hattori
Publikováno v:
Cancers; Volume 14; Issue 24; Pages: 6236
Introduction/Background: Chemoradiotherapy (CRT) followed by durvalumab, an immune checkpoint inhibitor, is the standard treatment for locally advanced non-small-cell lung cancer (NSCLC). Interstitial lung disease (ILD) is a life-threatening toxicity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8484ea253a14da3f748e96275bae4a3